Solvay SA
http://www.solvaypharmaceuticals-us.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Solvay SA
Scrip Asks…What Does 2023 Hold For Biopharma? Part 5: Technological Advances
The confluence of data science and molecular biology fuels expectations among biopharma industry leaders for another year of breakthrough innovation in human therapeutics. More than 70 executives and experts reveal what they are most excited about on the technology front.
Scrip Asks...What Does 2023 Hold For Biopharma? Part 2: M&A And Partnering
Deal-making between big pharma and biotech looks set to rise with a looming patent cliff increasing the need for the former to replenish its pipelines. Meanwhile, biotechs need partners to help them advance amid the ongoing big freeze on raising cash on public markets.
Wave Banks $170m Upfront In GSK Oligonucleotide Deal, Analysts Back Shift To Partnership Model
The US biotech has out-licensed a preclinical candidate to GSK as the firms pair up to discover and develop multiple oligonucleotide assets.
Deal Watch: OrsoBio Reveals Its Metabolic Health Focus With Four Licensing Pacts
California biotech also notes prior licensing deal with Gilead for mitochondrial candidate. Twentyeight-Seven acquires RNA-splicing cancer candidate from Basilea.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
- Other Names / Subsidiaries
-
- Laboratories Ireland Ltd.
- Innogenetics nv
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice